6CM4

Structure of the D2 Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.867 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.226 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone.

Wang, S.Che, T.Levit, A.Shoichet, B.K.Wacker, D.Roth, B.L.

(2018) Nature 555: 269-273

  • DOI: 10.1038/nature25758
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metabolism and hormonal secretion. Correspondingly, dysregulation of the dopaminergic system has been implicated in ...

    Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metabolism and hormonal secretion. Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases such as schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, and nausea and vomiting. The actions of dopamine are mediated by a family of five G-protein-coupled receptors. The D2 dopamine receptor (DRD2) is the primary target for both typical and atypical antipsychotic drugs, and for drugs used to treat Parkinson's disease. Unfortunately, many drugs that target DRD2 cause serious and potentially life-threatening side effects due to promiscuous activities against related receptors. Accordingly, a molecular understanding of the structure and function of DRD2 could provide a template for the design of safer and more effective medications. Here we report the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone. The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and highlights structural determinants that are essential for the actions of risperidone and related drugs at DRD2.


    Organizational Affiliation

    Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7365, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
D(2) dopamine receptor, endolysin chimera
A
430Homo sapiensEnterobacteria phage T4
This entity is chimeric
Mutation(s): 0 
Gene Names: DRD2, E
EC: 3.2.1.17
Find proteins for P14416 (Homo sapiens)
Go to Gene View: DRD2
Go to UniProtKB:  P14416
Find proteins for P00720 (Enterobacteria phage T4)
Go to UniProtKB:  P00720
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
OLA
Query on OLA

Download SDF File 
Download CCD File 
A
OLEIC ACID
C18 H34 O2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N
 Ligand Interaction
8NU
Query on 8NU

Download SDF File 
Download CCD File 
A
3-[2-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
C23 H27 F N4 O2
RAPZEAPATHNIPO-UHFFFAOYSA-N
 Ligand Interaction
PEG
Query on PEG

Download SDF File 
Download CCD File 
A
DI(HYDROXYETHYL)ETHER
C4 H10 O3
MTHSVFCYNBDYFN-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.867 Å
  • R-Value Free: 0.249 
  • R-Value Work: 0.226 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 50.979α = 90.00
b = 72.523β = 90.00
c = 151.307γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
HKL-3000data reduction
PHENIXrefinement
HKL-3000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
NIHUnited StatesRO1MH61887
NIHUnited StatesU19MH82441
NIHUnited StatesGM59957
National Cancer InstituteUnited StatesP30CA016086
National Cancer InstituteUnited StatesACB-12002
National Institute of General Medical SciencesUnited StatesAGM-12006
Department of Energy (United States)United StatesDE-AC02-06CH11357

Revision History 

  • Version 1.0: 2018-03-14
    Type: Initial release
  • Version 1.1: 2018-03-21
    Type: Database references
  • Version 1.2: 2018-04-11
    Type: Data collection, Database references